Pressure BioSciences Pops after Positive New Data

Shares of Pressure BioSciences

are seeing much strength after it was revealed that the company's technology offers high probability of biomarker discovery and drug development. Pressure BioSciences announced that data supporting important advantages of PBI's powerful and enabling Pressure Cycling Technology Platform were presented last week at the 56th Annual Meeting of the Biophysical Society in San Diego, CA and this week at the 8th Annual US Human Proteomic Organization Conference in San Francisco, CA. The development of highly sophisticated analytical tools for the research laboratory has enabled a greater understanding of complex biological molecules, including proteins. One such method, Electron Paramagnetic Resonance spectroscopy, has been shown to provide key information on the structure, flexibility, and function of proteins. This information is crucial to the development of new therapeutics, vaccines, and diagnostics. Currently, shares of Pressure BioSciences is trading higher by about 7.98% at $0.6492 per share.